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Original Article
Do Clinical Manifestations of Systemic Lupus Erythematosus in Pakistan
correlate with rest of Asia?
Malik Anas Rabbani2, Bilal Karim Siddiqui1, Muhammad Hammad Tahir1, Bushra Ahmad1, A Shamim1,
Shahid Majid1, Syed Sohail Ali1, Syed Mansoor Ahmed Shah1, Aasim Ahmad2.
Department of Medicine, the Aga Khan University Hospital1, Department of Nephrology, the Kidney Center, Post Graduate 
Training Institute2, Karachi. 
Abstract 
Objective: Systemic Lupus Erythematosus (SLE) is known to be different among people with differ-
ent racial, geographical and socio-economic back grounds. Asia has diverse ethnic groups broadly,
Orientals in the East and Southeast Asia, Indians in South Asia and Arabs in the Middle East. These
regions differ significantly from the Caucasians with reference to SLE. The purpose of this study
was, therefore, to delineate the clinical pattern and disease course in Pakistani patients with SLE
and compare it with Asian data.
Methods: Patients with SLE fulfilling the clinical and laboratory criteria of the American Rheumatism
Association admitted at the Aga Khan University Hospital between 1986 and 2001 were studied by
means of a retrospective review of their records. The results were compared with various studies in
different regions of Asia. 
Results: Demographically, it was seen that SLE is a disease predominantly of females in their third
decade, which is generally consistent with Asian data. There was less cutaneous manifestations,
arthritis, serositis, haematological and renal involvement compared to various regions in Asia. The
neurological manifestations of SLE, however, place Pakistani patients in the middle of a spectrum
between South Asians and other Asian races. 
Conclusion: This study has shown that the clinical characteristics of SLE patients in our country
may be different to those of other Asian races. Although our population is similar to South Asians,
but clinical manifestations of our SLE patients are considerably different, suggesting some unknown
etiology. Further studies are required to confirm the above results and to find statistically sounder
associations (JPMA 56:222;2006).
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Introduction
The trend of survival over the past few
decades of Systemic Lupus Erythematosus (SLE) has
improved but, at the same time the incidence has
increased three fold.1 The exact underlying
mechanisms behind clinical findings and etiologic
events preceding and causing disease  onset   remain
largely unclear; however, there is substantial circum-
stantial evidence that the development of SLE is
dependent on enviromental and genetic factors.2
Being the largest continent, both by area and
population, Asia encompasses people of different
socio-cultural background with diverse ethnic groups
broadly Orientals in East and Southeast Asia, Indians
in South Asia and Arabs in the middle east. Race has
been shown to be a major predictor of clinical mani-
festations of SLE, laboratory and serologic tests, and
disease related morbidity.3,4 Comparative studies
have shown that SLE has a higher prevalence, mor-
bidity and mortality in the Oriental population in
comparison to the Caucasians.5,6 Although there were
no major differences in outcomes of SLE among var-
ious Arab countries7, Arabs as a whole have different
clinical characteristics when compared to others.8,9
The prevalence of SLE in India is low; however, it is
not uncommon in South East Asian region.6,10 Also,
studies have shown that clinical manifestations of
SLE in India4 are similar to those in other South
Asian countries.11 Moreover, the data on the charac-
teristics of SLE in Pakistan is scarce with very few
citations in the international literature. The purpose of
this study was, therefore, to delineate the clinical pat-
tern and disease course in Pakistani patients with SLE
and to compare it with other Asian populations.
Patients and Methods
Medical charts of patients with SLE fulfilling the
clinical and laboratory criteria of the American
Rheumatism Association (ARA) admitted to the Aga
Khan University Hospital, Karachi, Pakistan between
1986 and 2001 were reviewed retrospectively. 
Clinical and laboratory manifestations
meeting the ARA criteria recorded were: malar rash,
discoid rash, photosensitivity, oral ulcers, arthritis,
serositis including pleuritis (history of pleuritic pain
or rub, or pleural effusion) or pericarditis
(documented by ECG or pericardial rub or evidence
of pericardial effusion on echocardiography), renal
disorder (elevated serum creatinine or persistent
proteinuria  >0.5 g/day or active cellular casts),
neurological disorder (seizures or psychosis in the
absence of other causes), haematological disorder
(haemolytic anaemia with reticulocytosis or
leucopenia defined as white cell count <4000/3mm
on two or more occasions or lymphopenia defined as
lymphocyte count <1500/3mm on two or more
occasions, or thrombocytopenia defined as platelet
count <100000/3mm not due to drugs or infection,
immunologic disorder (presence of anti-double-
stranded DNA antibody or antibody to Smith nuclear
antigen), or antinuclear antibody or antiphospholipid
antibodies. A patient was diagnosed with SLE if four
of the above criteria were met.
Clinical and laboratory data were collected
according to an established protocol, which included
a standard haematological and immunologic profile
(complete blood count, erythrocyte sedimentation
rate, serum electrolytes, serum creatinine, 24 hours
urinary protein and creatinine clearance and various
immunological tests including ANA, antibodies to
double-stranded DNA [dsDNA], anti-Smith
antibodies, rheumatoid factor [RF], antineutrophilic
cytoplasmic antibodies [ANCA], antiphospholipid
antibodies, and serum complement levels. 
The Statistical package for social science
SPSS 10.5 was used for data analysis. Chi square
comparison of proportions was used to compare our
results with other studies from Asia. The difference




A total of 198 patients were identified during
period of 1986 and 2001 who met American
Rheumatism Association criteria. Of these, 86.9%
(n=172) were females and only 12.1% (n=24) were
male patients. The mean age of presentation was 31
years (range 14-76 years). Mean duration of follow-
up was 34 months (range 4-179 months). The com-
parisons of demographics with other studies are
depicted in Table 1.
Clinical findings
Malar rash was present in 29% (n=56).
Discoid lupus in 14% (n=27), photosensitivity in 6%
(n=12) and alopecia in 22% (n=44) patients.  At the
time of presentation, 53% (n=105) patients were
febrile. There were variable occurrences of renal,
central nervous system (CNS), serosal,
haematological, and articular involvement. Serosal
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Malar Rash 29 56 <0.001 60 <0.001 58.5 <0.00001
Discoid Rash 14 12 0.417 10 0.1170 7 <0.001
Photosensitivity 6 35 <0.001 31 <0.001 48 <0.0001
Alopecia 22 84 <0.001 - -
Oral Ulcers 20 11 <0.05 20 0.948 55 <0.001
Arthropathy 38 84 <0.01 51 0.3195 85 <0.001
Serositis 29 19 <0.01 21 <0.05 22 <0.05
Renal 33 50 <0.001 54 <0.001 73 <0.0001
Neurological 29 5 <0.001 4 <0.001 51 <0.0001
Seizures 4 3 0.4456 -
Psychosis 4 3 0.4456 -
Leukopenia 22 32 < 0.01 -
Thrombocytopenia 26 25 0.820 -
Table 1. Comparison of clinical features of SLE among Pakistan with Studies in people of Oriental (Hong Kong and Singapore)
and South Asian Ethnicity (India).




p value Saudi Arabia18 %
(n=87)
p value Lebanon7 %
(n=100)
p value
Malar Rash 29 43 <0.05 56 <0.001 52 <0.001
Discoid Rash 14 10 0.321 18 0.360 19 0.277
Photosensitivity 6 48 <0.001 26 <0.001 16 <0.001
Alopecia 22 44 <0.001 - - - -
Oral Ulcers 20 33 <0.001 18 0.796 40 <0.001
Arthropathy 38 87 <0.001 91 <0.001 - -
Serositis 29 - 56 <0.001 40 0.051
Renal 33 37 0.458 63 <0.001 50 <0.001
Neurological 29 23 0.57 25 0.543 19 0.067
Seizures 4 - - - - 19 <0.001
Leukopenia 22 83 <0.001 33 0.037 17 0.33
Thrombocytopenia 26 26 0.974 20.7 0.256 33 0.198
Table 2. Comparison of clinical features of SLE among Pakistan with Studies in people of Arabic Ethnicity 
(Kuwait, Saudi Arabia and Lebanon).
Table 3. Comparison of frequency of autoantibody among Pakistani patients and other populations 

















ANA 86 87 94 - 98 98 89.5 -
dsDNA 74 50 58 65 67 93 97 43
Anti-Smith 50 - 13 12 31 40 33 26
Cardiolipin 35* - 9 -
* Anticardiolipin Antibodies were available only in 26 patients.
involvement was noted in 29% (n=56) patients.
Pleural effusion was found in 19% (n=33) patients
and pericardial effusion was present in 9% (n=18).
Although symptomatic arthralgias were noted in
almost all patients, articular involvement was noted
in 38% (n=76) patients. CNS involvement was noted
in 29% (n=56) patients, of whom 15% presented with
frank psychosis and 14% had seizures at some stage
during the course of illness. 
Laboratory findings at presentation
Complete  blood  count  revealed  leucopenia 
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in 22% (n=44), lymphopenia in 54% (n=107) and
thrombocytopenia in 26% (n=51). Five percent
patients presented with pancytopenia (n=9). Renal
involvement was found in 33% (n=65),of which 50%
had raised serum creatinine, 67% microscopic
hematuria, 87% active urinary casts, and 74%
proteinuria detectable on urine dipstick. Among
patients with proteinuria, only 55% had proteinuria in
nephrotic range. On renal biopsy, 64% of the cases
had WHO class 4, 17% had class 5, 14% had class 3
and 5% had class 2 histological findings. ANA was
positive in 86% (n=168) patients, Anti-dsDNA test
results were positive in 74% (n=146) while 50%
(n=99) tested positive for anti-Sm antibodies. No
other antibodies, such as RF, ANCA, or
antiphospholipid antibodies were found in clinically
significant titers. 
Outcome and Follow up
Significant numbers of patients (40%) were
either noncompliant or irregular with follow-up
visits, so the ultimate outcome of their disease could
not be clearly determined. The in-hospital mortality
was 16% (n=32). The most common cause of death
was overwhelming infections.
Comparison with Oriental ethnicity
The prevalence of malar rash,
photosensitivity, alopecia, arthropathy, leucopenia,
and renal symptoms were found to be less when
compared to Oriental populations12,13; however,
serositis and neurological symptoms were more
prevalent in our patients (Table 1).  
Comparison with Arabs
The prevalence of malar rash,
photosensitivity, alopecia, oral ulcers, arthropathy,
serositis and leucopenia were low in contrast to find-
ings in Arabs.11,14,15 (Table 2)
Comparision with Indian population
Malar rash, photosensitivity, oral ulcers,
arthropathy, renal and neurological symptoms were
found to be less prevalent in our series than Indian
patients.16 Discoid rash and serositis was found to be
more rampant in our study population (Table 1).
Auto-antibodies profile
The presence of anti Smith antibodies was
more prevalent in our patients when compared to
other populations (p < 0.01). The comparison of
prevalence of auto-antibodies is shown in Table 3.
Discussion
SLE is acknowledged as a multigenic disease
in which environmental factors are likely to modulate
expression of susceptibility genes.13 In addition to
the environment, evidence supports the concept that
the geographic origin of populations and age affect
the presentation and clinical course of SLE. There
have been several studies dealing with late onset SLE
suggesting that age at onset modifies the clinical
expression of the disease in terms of onset, clinical
presentation, pattern of organ involvement and
serological finding.17 Age also influences the
serological manifestation of SLE. Anti-dsDNA
antibodies and anticardiolipin tended to occur less
frequently in older patients.17 The mean age of onset
of the disease in our series, however, was 31 years
which is consistent with the reported literature from
Asia.5-8, 11, 18 Although females predominated the
disease, the finding was more remarkable in
Sri Lankan11 and Oriental populations.5, 18
SLE diagnoses have increased and it seems
sensible to attribute this to improved diagnostic tests
and the recognition of mild disease manifestation.
Although arthritis, arthralgia and rash remain the
most frequent signs of SLE, there is an increase in the
frequency of serositis and haematocytopenias in older
patients.19 The most frequent mode of presentation in
our population was also arthritis and arthralgias
followed by renal symptoms, malar rash, serositis,
and neurological symptoms. These clinical features
were even more frequent in Oriental
populations5, 10, 18 whereas the CNS manifestations
were found to be more prevalent in our series.
Conversely, individual CNS manifestations like
seizures and psychosis were not found to be signifi-
cant. Kasitanon et al from Thailand described a much
higher proportion of seizures20 while other reports
found lower incidences among Chinese population.18
Ward et al found that blacks had a lower prevalence
of photosensitivity with a higher prevalence of dis-
coid rash, as compared to Whites.15 Similar findings
were noted in another study from Singapore.5
Renal involvement in SLE may be quite
diverse and may vary from no clinical abnormalities
to rapidly progressive renal failure. The incidence of
Lupus nephritis was found to be much higher in
Chinese population6,18 as compared to our findings.
Furthermore, a high incidence of lupus nephritis was
reported from Malaysia with 74% of patients having
significant proteinuria and half of these had an
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associated Nephrotic Syndrome.21 Despite the fact
that factors like arthritis, cutaneous manifestations
and leukopenia may be protective against
mortality,14,22 the overall pattern generally showed
higher morbidity in the Orientals than in our patients.
When compared to the Arabs,7-9 our patients
had lower prevalence of malar rash, photosensitivity,
oral ulcers, arthritis, serositis, renal disorders and
leukopenia. However, lupus nephritis was not found
to be significantly higher in Kuwait suggesting
variable prevalence of Lupus Nephritis in the Arabs.8
The incidence of lymphopenia in Arab population
was reported to be 70%7 which is significantly
higher than our population. However, there was not
any significant difference in other haematological
abnormalities like thrombocytopenia which carries a
poorer prognosis.22 Moreover, the prevalence of
serositis and pleural effusion in our series was similar
to the study from Oman which showed that pleural
effusion complicated 40% of SLE patients with
serositis.15
South Asians are generally similar to Pakistani
population geographically, racially, socio-
economically and by culture. Paradoxically, when
compared to the Indians23 malar rash,
photosensitivity, oral ulcers, arthritis, serositis, renal
disorders and CNS manifestations were all found to
be statistically less in our population. Galapatty et al
from Sri Lanka reported mucocutaneous features in
98%, alopecia in 87%, lupus nephritis in 69%,
haematological disorders in 54%, neurological
involvement in 42% and serositis in 25% patients.11
These findings are in contrast to our findings showing
that our lupus patients generally do not present as
other South Asians. 
About half of our patients had anti Smith
antibodies which is higher than most of the available
data.8-10,18 This may reflect a different genetic back-
ground of our patients compared to the others.
Although anti Smith antibodies are associated with a
higher prevalence of lupus nephritis,16 some studies
have shown no differences.24 There was no
difference in the prevalence of other antibodies like
ANA and anti dsDNA as compared to Chinese18 and
Indians.23
As our study was conducted in a single city in
a tertiary care hospital, it may not represent the coun-
try as a whole. However, Karachi is a multiethnic city
and may be a true representative of the whole country
and all its races. 
Conclusion
Appreciation of the clinical differences may
be important when attempting to assess for the devel-
opment of certain clinical manifestations in individ-
ual patients and when attempting to define immuno-
genetic associations within groups of patients with
SLE. This study has shown that the clinical character-
istics of SLE patients in this country may be different
to those of other Asian races. Although we can
assume that our population is genetically, environ-
mentally and socioeconomically similar to South
Asians, yet clinical manifestations of our SLE
patients are considerably different suggesting some
unknown etiology. The Antibody patterns may also
point to a different genetic etiology of SLE in
Pakistan. We had significantly lower incidence of
lupus nephritis, which is the major cause of morbidi-
ty and mortality in SLE, when compared to many
other Asian studies. The Neurological manifestations
of SLE, however, place Pakistani patients in the mid-
dle of a spectrum between South Asians and other
Asian races. Our patients also have lower incidence
of cutaneous, haematological and arthritic involve-
ment.
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